CURRICULUM VITAE

David M Katz, MD

OFFICE ADDRESS:                                    Bethesda Neurology, LLC

3202 Tower Oaks Blvd, Suite 330

N Bethesda, 

301-540-2700 (office phone)

866-328-4322 (fax)

          WEBSITE:                                 BethesdaNeurology.com

SUBSPECIALTY:  Neuro-Ophthalmology                                   

SPECIALITY: Adult Neurology

EDUCATION:

UNDERGRADUATE 

Colgate University

Hamilton, NY

BA in Neuroscience      

1979-1983

MEDICAL SCHOOL   

SUNY/Buffalo School of Medicine

Buffalo, NY

1984-1988

INTERNSHIP

Millard Fillmore Hospital/SUNY Buffalo

Buffalo, NY

Internal Medicine

1988-1989

NEUROLOGY RESIDENCY 

Duke University Medical Center

Durham, NC 

Neurology Residency

1989-1992, Chief Resident: 91-92

NEURO-OPHTHALMOLOGY FELLOWSHIP 

University of Michigan Kellogg Eye Center

Ann Arbor, MI

1992-1993

BOARD CERTIFICATION: 

Diplomate, American Board of Neurology, 1994 Lifetime Certification

MEDICAL LICENSURE: 

Maryland: D0052447

DC: MD30630

Virginia: 0101232630

FACULTY APPOINTMENTS: 

Clinical Assistant Professor of Ophthalmology

Georgetown University Medical Center

Washington, DC, 2012-

Clinical Associate Professor of Ophthalmology and Neurology, and Director of Neuro-Ophthalmology Services

Howard University School of Medicine

Washington, DC, 1997-

Fellow, North American Neuro-Ophthalmology Society 2014-

HOSPITAL AFFILIATIONS:

Suburban Hospital/Johns Hopkins Medicine

Bethesda, MD, 1997-

HONORS AND AWARDS:

Steering Committee, Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

“Super Doctors”, Washington Post

“Top Neurologists”, Best Doctors

“Top Neurologists”, Consumer Checkbook

“Top Doctors”, Northern Virginia Magazine

“Neuro-Ophthalmology Medical Mystery Case” Washington Post Health Section 11/22/16

PROFESSIONAL SOCIETIES:

-Maryland Board of Physicians, Neurology  Consultant

-Washington Clinical Pathological Society (WCP)

-DC Area Neuro-Immunology Group (DANG)

-North American Neuro-Ophthalmology Society     (NANOS)

-Montgomery County Medical Society (MCMS)

-MedChi

-American Medical Association (AMA)

BIBLIOGRAPHY:

Yousuf, Guiseppi, Katz, et al. Emergency department presentation of retinal artery occlusion. Ophthalmol Retina 2021

Olds J, Hills W, Warner J, Falardeau J, Egan R, Cornblath W, Lee A, Frishberg B, May M, Turbin R, Katz D, Charley J, Pelak V. Posterior cortical atrophy: patient characteristics from a clinical data registry. Front in Neurol 2020,11:358-71.

Zhou Y, Walker R, Katz D, Weir R, Trouth, A. Varicella-zoster reactivation resulting in stroke and progressive outer retinal necrosis: case report and literature review. ECNeurology 2017, 6.5:238-42

Katz DM and Trobe JD. Is there treatment for nonarteritic anterior ischemic optic neuropathy (NAION)? Curr Opin in Ophthalmol 2015,26(6):458-463

De Lott LB, Burke JF, and Michigan Neuro-ophthalmology Research Consortium. The use of laboratory markers in deciding whether to perform temporal artery biopsy. JAMA Ophthalmol 2015, 133(5):605-8

Wall M, Kupersmith M, Kieburtz K, Corbett J, Feldon S, Friedman D, Katz D, et al. The Idiopathic Intracranial Hypertension Treatment Trial. Clinical profile at baseline. JAMA Neurol 2014, 71(6):693-701

Wall M, McDermott M, Kieburtz K, Corbett J, Feldon S, Friedman D, Katz D, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the Idiopathic Intracranial Hypertension Treatment Trial. JAMA 2014, 311(16):1641-1651

Vision and Lupus. Lupus Now, Spring 2014

MedLink Neurology. Sixth nerve palsy review. 1998-

Katz DM. Neuroclinical journal review. Journal of Neuro-ophthalmology. 2003, 23(2):170-

175

Katz DM, commentator on: Remigio D and Wertenbaker C. Post-operative bilateral vision

loss. Surveys of Ophthalmology 2000, 44:426-432

Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic neuropathy following lumbar spine surgery. Archives of Ophthalmology.   1994, 112 (7): 925-931

Katz DM, Trobe JD, Dauser R, Marazsko K.  Shunt failure without ventriculomegaly proclaimed by ophthalmic findings. Journal of Neurosurgery. 1994,81:721-725

Waniewski RA, Katz DM, Kimelberg HK. Low-affinity binding of 3H-imipramine to primary astrocyte cultures. Biochemical Pharmacology. 1987; 36 (5):639-46

Kimelberg HK, Katz DM. Regional differences in 5-hydroxytryptamine and catecholamine uptake in primary astrocyte cultures. Journal of Neurochemistry. 1986;47:1647-52

Kimelberg HK, Katz DM. High-affinity uptake of serotonin into immunocytochemically identified astrocytes.  Science. May 17, 1985; 228:889-91

Katz DM, Kimelberg HK.  Kinetics and autoradiography of high affinity uptake of serotonin by primary astrocyte cultures.  Journal of Neuroscience. 1985; 5 (7): 1901-8

Kimelberg, HK, Katz DM. High-affinity uptake of 3H-serotonin by primary astrocyte culture from rat brain. Society for Neuroscience Abstracts. 1984; 10:766

ABSTRACTS:

DeLott L, Anderson D, Dotan S, Katz D, et al. Applying laboratory data in temporal artery biopsy decisions. North American Neuro-Ophthalmology Society Meeting, March, 2014, Puerto Rico

Osborne B, Katz DM, Khan N. Bilateral compressive optic neuropathy due to idiopathic hyperostosis of the skull. North American Neuro-Ophthalmology Society Meeting, February, 2013, Snowbird, UT

Shah D, Mark A, Katz DM. “Dark Halo Sign” on T1-Weighted Images: An

Ominous Finding of Aggressive Sphenoid Sinusitis. American Society of Neuroradiology, May,

2010, Boston, MA

Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic

neuropathy following lumbar spine surgery. North American Neuro-Ophthalmology Society

Meeting, March 1993, Big Sky, MT

Katz DM, Trobe JD, Dauser R, Marazsko K.  Shunt failure without ventriculomegaly proclaimed by ophthalmic findings. North American Neuro-Ophthalmology Society Meeting, March 1993, Big Sky, MT

CLINICAL TRIALS:

Phase IV 5-10 year observational trial (Verismo) of ocrelizumab for the treatment of multiple sclerosis to determine incidence of breast cancer and other malignancies. 2019-

Phase III, randomized, masked trial comparing maximal medical therapy vs. optic nerve sheath fenestration vs. ventriculoperitoneal CSF shunting in subjects with moderate to severe vision loss due to idiopathic intracranial hypertension (SIGHT). 2019-2020

Phase III, randomized, double-masked evaluating the efficacy and safety of RPh201 (Regenera) subcutaneously twice weekly to test for regeneration in patients with stable non-arteritic anterior ischemic optic neuropathy (NAION). 2018-2020

Open-label intervention study assessing the efficacy and safety of long-term treatment with idebenone (Raxone) in Leber’s Hereditary Optic Neuropathy. 2017-2021

Phase II/III, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute non-arteritic anterior ischemic optic neuropathy (NAION). 2016-2019

Multi-center international trial collecting retrospective data on patients with meningiomas affecting the anterior visual pathways who had undergone surgery. Coordinated by the University of Michigan/WK Kellogg Eye Center. Jonathan Trobe, MD director, 2015-17

Non-Arteritic Ischemic Optic Neuropathy natural history trial (NAION PERCEPTION Study). 2013-2016

ESTEEM phase IV trial of Tecfidera (dimethyl fumarate) for relapsing-remitting MS. 2013-2021

Multi-center US trial collecting data on 400 patients with giant cell arteritis. Coordinated by the University of Michigan/WK Kellogg Eye Center. Jonathan Trobe, MD director, 2012-14

Multi-center US trial collecting data on minority patients with giant cell arteritis. Coordinated by Wills Eye Hospital. 2013

Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Phase III, placebo controlled clinical trial. Principal Investigator. NIH/NEI sponsored. 2010-14

Evaluate Patient Outcomes Study (EPOC). Phase IV safety and tolerability of fingolimod in MS. Principal Investigator. 2011-14

STATIFY-2. JC virus antibody program in patients with MS. Phase IV study. Principal Investigator. 2010-14

Tysabri Global Observational Program in Safety (TYGRIS). Phase IV study. Principal Investigator. 2010-14

PRESENTATIONS:

Latest treatment for optic neuritis and MS. First annual Ophthalmology Times EyeConference, virtual meeting, December, 2021

What’s new in MS. Holy Cross Hospital Neuroscience Symposium, Silver Spring, MD November, 2021

Transient visual loss and visual field interpretations. Montgomery County Optometric Society meeting, Bethesda, MD September, 2019

Management of binocular diplopia. DC regional optometry review course, McLean, Va, October, 2018

Diplopia Review. Montgomery County Optometric Society meeting, Bethesda, MD, March, 2018

Novel treatment for NAION (QRK207 clinical trial). Montgomery County Optometric Society meeting, Bethesda, MD, October, 2017.

Giant Cell Arteritis and Non-Arteritic Ischemic Optic Neuropathy Review. DC regional optometry review course, McLean, VA, June, 2017

Non-Arteritic Ischemic Optic Neuropathy Review. Howard University Ophthalmology Residents’ Day. June, 2017

What’s new in MS. Howard University Ophthalmology Residents’ Day. June, 2016

What’s new in MS. Montgomery County Optometric Society meeting, Bethesda, MD, May, 2016

What’s new in MS. Washington Clinical-Pathological Society meeting, February, 2016

Severe optic neuritis and/or transverse myelitis most often due to NMO/Devic’s in minority population. Howard University Ophthalmology Residents’ Day. June, 2015

Parkinson’s Disease and Visual Issues. Leisure World Parkinson’s Society Meeting, March, 2015

Idiopathic Intracranial Hypertension Treatment Trial presentation of clinical trial results. Georgetown University Neurology Department dinner meeting, Chevy Chase, MD October, 2014

Giant Cell Arteritis Review. Montgomery County Optometric Society meeting, Bethesda, MD, September, 2014

Wernicke’s encephalopathy misdiagnosis. Invited lecturer, Virginia Society of Eye Physicians & Surgeons Annual Meeting. Richmond, VA, June, 2014

IgG4-Related orbital inflammation, a new entity with systemic manifestations. Washington Clinical-Pathological Society meeting, May, 2014

Review of blepharospasm. Benign Essential Blepharospasm Research Foundation (BEBRF) meeting. Holy Cross Hospital, October, 2013

IgG-4 may be a common cause of orbital inflammation. Howard University Ophthalmology Resident’s Day. June, 2013

Case presentations at the Washington Hospital Center/Georgetown Neuro-ophthalmology Saturday Conferences, November 1997-

Idiopathic intracranial hypertension and papilledema review. Montgomery County Optometric Society CME meeting, Bethesda, MD, May, 2013

Neuro-ophthalmological diagnoses you can’t afford to miss. Montgomery County Optometric Society meeting, Bethesda, MD, March, 2013

Atypical mad cow disease vs. Wernicke’s encephalopathy. Washington Clinical-Pathological Society meeting, January, 2013

Vision issues and Parkinson’s Disease. Parkinson Foundation of the National Capital Area. November, 2012

A victim of herd mentality. Invited lecturer, University of Michigan/Kellogg Eye Center Alumni Day. September, 2012

Could giant cell arteritis be caused by an infection? Howard University Ophthalmology Residents’ Day. June, 2012

Ophthalmological complications of the new MS drug, Fingolimod. Howard University Ophthalmology Residents’ Day. June, 2011

Progressive Multifocal Leukoencephalopathy in a previously healthy 70-year-old male. Washington Clinical Pathological Society meeting, October, 2011

Idiopathic Intracranial Treatment Trial. Howard University Ophthalmology Residents’ Day. June, 2010

Is there treatment for non-arteritic anterior ischemic optic neuropathy? Howard University Ophthalmology Residents’ Day. June, 2009

Ocular coherence tomography in optic neuritis/MS. Howard University Ophthalmology Residents’ Day. June, 2008

Toxic optic neuropathies. Howard University Ophthalmology Residents’ Day. June, 2007

What’s new in MS. Howard University Ophthalmology Residents’ Day. June, 2006

Ischemic optic neuropathy update. Howard University Ophthalmology Residents’ Day. June, 2005

Intracranial hypotension causing meningeal enhancement and sixth nerve palsies. Howard University Ophthalmology Residents’ Day. June, 2004

Steroid dependant optic neuropathy due to neuro-sarcoidosis. Howard University Ophthalmology Residents’ Day. June, 2003         

Unexplained bilateral vision loss in a young female due to occult macular cone dystrophy. Howard University Ophthalmology Residents’ Day. June, 2002

Update on optic neuritis and its relationship to MS. Presented at the Howard University Ophthalmology Residents’ Day. June, 2001

Unusual cause of idiopathic intracranial hypertension. Presented at the Howard University

Ophthalmology Residents’ Day. June, 2000

Neuro-ophthalmologic complications of ventriculo-peritoneal shunt failure. Presented at the

Howard University Ophthalmology Residents’ Day. June, 1999

Optic neuritis and diplopia in multiple sclerosis. Presented at the Fairfax Hospital Multiple Sclerosis Society. November, 1999        

Risk factor modification in stroke prevention. Presented at the Suburban Hospital Outreach

Center. May, 1998

Results of the Optic Neuritis Treatment Trial. Grand rounds presentation at MetroWest Medical

Center, Framingham, MA. January, 1994

Revised 11/17/2021